Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Inclusion Criteria:

1. At least 18 years of age at the time of signing the informed consent form (ICF)

2. At Screening and Randomization: AOBP SBP of ≥135 and ≤180 mmHg plus AOBP DBP of ≥65and ≤110 mmHg, or AOBP DBP of ≥90 and ≤110 mmHg

3. Taking between 2 and 5 AHT medications,

4. History of hypertension lasting at least 6 months prior to Screening

5. Body mass index (BMI) of ≥18 kg/m2 at Screening

Exclusion Criteria:

1. Women who are pregnant, plan to become pregnant, or are breastfeeding

2. Participation in a study involving any investigational device or small-molecule drugwithin 4 weeks or 6 months for biologic (antibody) drugs prior to the ScreeningVisit

3. eGFR <45 mL/min/1.73m2 at Screening, calculated using the Chronic Kidney DiseaseEpidemiology Collaboration (CKD-EPI) formula

4. Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization

5. Serum sodium <135 mmol/L (corrected for hyperglycemia) at Screening.

6. History of heart failure, myocardial infarction, stroke, or transient ischemicattack within 6 months prior to the Screening Visit.